JP2012508169A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508169A5 JP2012508169A5 JP2011534633A JP2011534633A JP2012508169A5 JP 2012508169 A5 JP2012508169 A5 JP 2012508169A5 JP 2011534633 A JP2011534633 A JP 2011534633A JP 2011534633 A JP2011534633 A JP 2011534633A JP 2012508169 A5 JP2012508169 A5 JP 2012508169A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fragment
- humanized anti
- seq
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/266,999 | 2008-11-07 | ||
| US12/266,999 US7902338B2 (en) | 2003-07-31 | 2008-11-07 | Anti-CD19 antibodies |
| PCT/US2009/061666 WO2010053716A1 (en) | 2008-11-07 | 2009-10-22 | Improved anti-cd19 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015117532A Division JP5951850B2 (ja) | 2008-11-07 | 2015-06-10 | 改良された抗ｃｄ１９抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012508169A JP2012508169A (ja) | 2012-04-05 |
| JP2012508169A5 true JP2012508169A5 (enExample) | 2012-11-15 |
| JP5762965B2 JP5762965B2 (ja) | 2015-08-12 |
Family
ID=42153175
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534633A Active JP5762965B2 (ja) | 2008-11-07 | 2009-10-22 | 改良された抗ｃｄ１９抗体 |
| JP2015117532A Active JP5951850B2 (ja) | 2008-11-07 | 2015-06-10 | 改良された抗ｃｄ１９抗体 |
| JP2016114443A Pending JP2017019765A (ja) | 2008-11-07 | 2016-06-08 | 改良された抗ｃｄ１９抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015117532A Active JP5951850B2 (ja) | 2008-11-07 | 2015-06-10 | 改良された抗ｃｄ１９抗体 |
| JP2016114443A Pending JP2017019765A (ja) | 2008-11-07 | 2016-06-08 | 改良された抗ｃｄ１９抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (9) | US7902338B2 (enExample) |
| EP (1) | EP2352523B1 (enExample) |
| JP (3) | JP5762965B2 (enExample) |
| CN (1) | CN102209556B (enExample) |
| AU (1) | AU2009311461B2 (enExample) |
| CA (1) | CA2742254A1 (enExample) |
| IL (1) | IL212701A (enExample) |
| WO (1) | WO2010053716A1 (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8420086B2 (en) | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| US8034352B2 (en) * | 2005-04-06 | 2011-10-11 | Ibc Pharmaceuticals, Inc. | Tetrameric cytokines with improved biological activity |
| US7608425B2 (en) * | 2004-07-23 | 2009-10-27 | Immunomedics, Inc. | Methods for protein expression in mammalian cells in serum-free medium |
| WO2009052431A2 (en) | 2007-10-19 | 2009-04-23 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
| AU2009313296B2 (en) * | 2008-11-07 | 2015-07-23 | National Jewish Health | Diagnosis and treatment of autoimmune diseases by targeting autoimmune-related B cells ("ABCs") |
| US9097717B2 (en) * | 2009-04-10 | 2015-08-04 | Osaka University | Methods of killing myeloma stem and precursor cells by administering anti-CD48 antibodies |
| CA2804501C (en) | 2010-07-06 | 2021-01-26 | Novartis Ag | Noro virus derived immunogenic compositions and methods |
| KR102117202B1 (ko) | 2011-08-16 | 2020-06-01 | 모르포시스 아게 | 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법 |
| EP2744515B1 (en) | 2011-08-16 | 2022-02-09 | MorphoSys AG | Combination therapy with an anti-cd19 antibody and a nitrogen mustard |
| HRP20200744T1 (hr) * | 2011-12-22 | 2020-07-24 | F. Hoffmann - La Roche Ag | Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida |
| ES2738310T3 (es) | 2012-10-12 | 2020-01-21 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas |
| AU2012395148B2 (en) | 2012-11-24 | 2016-10-27 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| AU2013360335B2 (en) | 2012-12-13 | 2017-12-07 | Immunomedics, Inc. | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| WO2017004144A1 (en) | 2015-07-01 | 2017-01-05 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| CA2905181C (en) | 2013-03-13 | 2020-06-02 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof for providing targeted therapy |
| CA2907397C (en) | 2013-03-15 | 2022-11-22 | Anthrogenesis Corporation | Modified t lymphocytes |
| JP6447933B2 (ja) | 2014-02-21 | 2019-01-09 | アイビーシー ファーマスーティカルズ，インコーポレイテッド | Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療 |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| FI3122757T3 (fi) | 2014-02-28 | 2023-10-10 | Hangzhou Dac Biotech Co Ltd | Varautuneita linkkereitä ja niiden konjugointikäyttötapoja |
| EP2990416B1 (en) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| PE20170676A1 (es) | 2014-09-09 | 2017-05-22 | Janssen Biotech Inc | Terapias de combinacion con anticuerpos anti-cd38 |
| US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| SI3204018T1 (sl) | 2014-10-07 | 2021-11-30 | Immunomedics, Inc. | Neoadjuvantna uporaba konjugatov protitelo-zdravilo |
| EA202092609A1 (ru) | 2014-12-04 | 2021-10-29 | Янссен Байотек, Инк. | Антитела к cd38 для лечения острого миелолейкоза |
| CN105837689B (zh) * | 2015-01-13 | 2020-06-19 | 博生吉安科细胞技术有限公司 | 抗cd19单克隆抗体及其制备方法 |
| BR112017024757A2 (pt) | 2015-05-18 | 2018-11-13 | TCR2 Therapeutics Inc. | composições e métodos para reprogramação de tcr utilizando proteínas de fusão |
| CA2986594C (en) | 2015-05-20 | 2025-06-10 | Tufts Medical Center, Inc. | Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
| EP3603672B1 (en) | 2015-05-26 | 2026-04-22 | Incyte Corporation | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof |
| WO2016201350A1 (en) * | 2015-06-12 | 2016-12-15 | Immungene, Inc. | Combination therapy for treatment of cancer |
| CA2989269C (en) | 2015-06-15 | 2020-09-22 | Robert Yongxin Zhao | Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule |
| CN107708734B (zh) | 2015-06-22 | 2022-01-11 | 詹森生物科技公司 | 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| AU2016281622C1 (en) | 2015-06-25 | 2021-11-18 | Immunomedics, Inc. | Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer |
| EP3319936B1 (en) | 2015-07-12 | 2025-12-17 | Hangzhou Dac Biotech Co., Ltd. | Bridge linkers for conjugation of cell-binding molecules |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| MX392561B (es) | 2015-08-21 | 2025-03-24 | Morphosys Ag | Combinación sinérgica de un anticuerpo anti-cd19 y un inhibidor de fosfoinositida 3-quinasa para usarse en el tratamiento de linfoma no hodgkin, leucemia linfocítica crónica y/o leucemia linfoblástica aguda. |
| ES2980794T3 (es) | 2015-09-15 | 2024-10-03 | Acerta Pharma Bv | Combinaciones terapéuticas de un inhibidor de CD19 y un inhibidor de BTK |
| HUE053366T2 (hu) | 2015-11-03 | 2021-06-28 | Janssen Biotech Inc | Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| KR102927822B1 (ko) * | 2016-01-29 | 2026-02-13 | 주식회사유한양행 | Pd-l1에 결합하는 항원 결합 단백질 |
| CN115932265B (zh) | 2016-05-30 | 2026-04-14 | 因塞特公司 | 预测cd19抗体治疗在患者中的治疗益处的方法 |
| CN109415440B (zh) | 2016-06-27 | 2022-12-06 | 莫佛塞斯公司 | 抗-cd19抗体制剂 |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| WO2018026953A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CN107793479B (zh) * | 2016-09-06 | 2024-02-06 | 上海吉倍生物技术有限公司 | 一种抗cd19抗体及其制备方法和用途 |
| MX2019003899A (es) | 2016-10-07 | 2019-08-14 | Tcr2 Therapeutics Inc | Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion. |
| WO2018069289A1 (en) | 2016-10-11 | 2018-04-19 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| WO2018075820A2 (en) | 2016-10-20 | 2018-04-26 | Celgene Corporation | Cereblon-based heterodimerizable chimeric antigen receptors |
| KR20230028571A (ko) | 2016-10-28 | 2023-02-28 | 모르포시스 아게 | 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도 |
| AU2016429272A1 (en) | 2016-11-14 | 2019-05-02 | Hangzhou Dac Biotech Co., Ltd. | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers |
| AU2017363311A1 (en) | 2016-11-22 | 2019-06-13 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| WO2018108106A1 (zh) | 2016-12-13 | 2018-06-21 | 科济生物医药（上海）有限公司 | 抗cd19的人源化抗体以及靶向cd19的免疫效应细胞 |
| IL297461B2 (en) | 2017-05-31 | 2024-09-01 | Morphosys Ag | Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment |
| DE102017215966A1 (de) * | 2017-09-11 | 2019-03-14 | BSH Hausgeräte GmbH | Haushaltsgerät mit Temperaturdetektor |
| CN111565751A (zh) | 2017-10-31 | 2020-08-21 | 詹森生物科技公司 | 治疗高危多发性骨髓瘤的方法 |
| SG11202011306TA (en) | 2018-05-16 | 2020-12-30 | Janssen Biotech Inc | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
| SG11202010469QA (en) | 2018-05-23 | 2020-11-27 | Adc Therapeutics Sa | Molecular adjuvant |
| CN108659128B (zh) * | 2018-05-30 | 2021-06-04 | 福州迈新生物技术开发有限公司 | 抗cd19蛋白的单克隆抗体及其细胞株、制备方法和应用 |
| CN109180798B (zh) * | 2018-09-04 | 2020-10-27 | 武汉原生药谷生物医药科技有限公司 | 一种增强型治疗性抗体及其应用 |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| CN111253487B (zh) * | 2018-12-03 | 2024-02-02 | 广东东阳光药业股份有限公司 | Cd19抗体及其应用 |
| AU2020267823A1 (en) | 2019-05-03 | 2021-11-11 | Incyte Corporation | Anti-CD19 therapy in patients having a limited number of NK cells |
| BR112021022682A2 (pt) | 2019-05-14 | 2022-02-22 | Provention Bio Inc | Métodos e composições para prevenir diabetes do tipo 1 |
| CN118994397A (zh) | 2019-05-21 | 2024-11-22 | 诺华股份有限公司 | 针对bcma的三特异性结合分子及其用途 |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| AU2020331963A1 (en) * | 2019-08-19 | 2022-03-03 | Elpis Biopharmaceuticals | Anti-CD19 antibodies and uses thereof |
| UA129546C2 (uk) * | 2019-09-16 | 2025-05-28 | Опсідіо, Ллк | Антитіла проти фактора стовбурових клітин і способи їх застосування |
| US12544437B2 (en) | 2019-10-04 | 2026-02-10 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant AAV |
| PH12022551009A1 (en) | 2019-10-31 | 2023-03-20 | Morphosys Ag | Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells |
| AU2020376305A1 (en) | 2019-10-31 | 2022-05-12 | Incyte Corporation | Anti-CD19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma |
| MX2022010549A (es) | 2020-02-26 | 2022-11-16 | Biograph 55 Inc | Moleculas de union compuestas que se dirigen a celulas b inmunodepresoras. |
| JP7641292B2 (ja) * | 2020-03-03 | 2025-03-06 | システィミューン， インク． | 抗ｃｄ１９抗体、その使用方法及び製造方法 |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| EP4168449A1 (en) | 2020-06-22 | 2023-04-26 | MorphoSys AG | Anti-tumor combination therapy comprising anti-cd19 antibody and polypeptides blocking the sirpa-cd47 innate immune checkpoint |
| MX2023003997A (es) | 2020-10-06 | 2023-06-15 | Xencor Inc | Biomarcadores, métodos y composiciones para el tratamiento de la enfermedad autoinmunitaria, que incluye el lupus eritematoso sistémico (les). |
| US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
| WO2022109611A1 (en) | 2020-11-20 | 2022-05-27 | Simcere Innovation, Inc. | Armed dual car-t compositions and methods for cancer immunotherapy |
| US20220184208A1 (en) | 2020-12-04 | 2022-06-16 | Morphosys Ag | Anti-cd19 combination therapy |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| WO2022251253A1 (en) | 2021-05-24 | 2022-12-01 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| WO2023073645A1 (en) | 2021-10-29 | 2023-05-04 | Takeda Pharmaceutical Company Limited | Therapy comprising anti-cd19 antibody and sumo-activating enzyme inhibitor |
| CN117980327A (zh) | 2021-11-03 | 2024-05-03 | 杭州多禧生物科技有限公司 | 抗体的特异性偶联 |
| JP2025513890A (ja) | 2022-04-13 | 2025-04-30 | ティクヴァ アロセル プライベート リミテッド | 治療用ｔ細胞製品 |
| IL318787A (en) | 2022-08-17 | 2025-04-01 | Incyte Corp | Treatment including ANTI-CD19 antibodies and EZH2 modulators |
| CN121263449A (zh) | 2023-03-21 | 2026-01-02 | 拜格拉夫55公司 | Cd19/cd38多特异性抗体 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861511B1 (en) | 1986-06-04 | 2005-03-01 | Bayer Corporation | Detection and quantification of neu related proteins in the biological fluids of humans |
| US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US6362325B1 (en) | 1988-11-07 | 2002-03-26 | Advanced Research And Technology Institute, Inc. | Murine 4-1BB gene |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ES2095876T3 (es) | 1989-06-02 | 1997-03-01 | Univ Johns Hopkins Med | Anticuerpos monoclonales contra la cadena beta de receptores de adhesion de leucocitos; procedimiento de produccion de estos anticuerpos y utilizacion |
| US5270196A (en) | 1989-10-20 | 1993-12-14 | Bristol-Myers Squibb Company | Arylsulfatase from streptomyces |
| US7041293B1 (en) | 1990-04-03 | 2006-05-09 | Genentech, Inc. | HIV env antibodies |
| FR2676058B1 (fr) | 1991-04-30 | 1994-02-25 | Hoechst Lab | Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers. |
| US5854416A (en) | 1991-11-14 | 1998-12-29 | The United States Of America As Represented By The Department Of Health And Human Services | Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor |
| US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| DE69333348T2 (de) | 1992-03-09 | 2004-09-16 | San Diego Regional Cancer Center, San Diego | Anti-idiotypischer Antikörper und seine Verwendung zur Diagnose und Therapie bei HIV-bezogenen Krankheiten |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| GB9314960D0 (en) | 1992-07-23 | 1993-09-01 | Zeneca Ltd | Chemical compounds |
| US6100389A (en) | 1995-04-21 | 2000-08-08 | Human Genome Sciences, Inc. | Polynucleotides encoding a human chemotactic protein |
| AU3272695A (en) | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| US6458349B1 (en) | 1995-06-02 | 2002-10-01 | Human Genome Sciences, Inc. | Chemokine β-4 polypeptides |
| US6537764B1 (en) | 1995-01-19 | 2003-03-25 | Children's Medical Center Corporation | Method of identifying inhibitors of C—C chemokine receptor 3 |
| US6312691B1 (en) | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
| US6949244B1 (en) | 1995-12-20 | 2005-09-27 | The Board Of Trustees Of The University Of Kentucky | Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof |
| US5798554A (en) | 1995-02-24 | 1998-08-25 | Consorzio Per La Ricerca Sulla Microelettronica Nel Mezzogiorno | MOS-technology power device integrated structure and manufacturing process thereof |
| WO1996036360A1 (en) | 1995-05-17 | 1996-11-21 | Regents Of The University Of Minnesota | Immunoconjugates comprising single-chain variable region fragments of anti-cd-19 antibodies |
| US5773292A (en) | 1995-06-05 | 1998-06-30 | Cornell University | Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood |
| US5646298A (en) | 1995-06-07 | 1997-07-08 | Procoron, Inc. | Cyclopropylindole prodrugs |
| US6174992B1 (en) | 1997-03-21 | 2001-01-16 | Human Genome Sciences, Inc. | Human endometrial specific steroid-binding factor I, II and III |
| US6962981B1 (en) | 1996-03-25 | 2005-11-08 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
| US6004780A (en) | 1996-03-26 | 1999-12-21 | Human Genome Sciences, Inc. | Growth factor HTTER36 |
| US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
| US6653104B2 (en) | 1996-10-17 | 2003-11-25 | Immunomedics, Inc. | Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells |
| US6043348A (en) | 1996-11-13 | 2000-03-28 | Lawman; Michael J. P. | Antibody recognizing a small subset of human hematopoietic cells |
| WO1998031818A2 (en) | 1997-01-21 | 1998-07-23 | Human Genome Sciences, Inc. | Tace-like and matrilysin-like polypeptides |
| US6605699B1 (en) | 1997-01-21 | 2003-08-12 | Human Genome Sciences, Inc. | Galectin-11 polypeptides |
| EP1012274B2 (en) | 1997-01-28 | 2011-06-15 | Human Genome Sciences, Inc. | Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l) |
| US6919433B2 (en) | 1997-03-14 | 2005-07-19 | Human Genome Sciences, Inc. | Antibodies to protein HPMBQ91 |
| US6951924B2 (en) | 1997-03-14 | 2005-10-04 | Human Genome Sciences, Inc. | Antibodies against secreted protein HTEBYII |
| US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| US6183744B1 (en) | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US6358508B1 (en) | 1997-06-11 | 2002-03-19 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR9 |
| US6956107B2 (en) | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
| US6861227B2 (en) | 1998-03-19 | 2005-03-01 | Human Genome Sciences, Inc. | Antibodies to cytokine receptor common gamma chain like |
| KR100508289B1 (ko) | 1998-04-21 | 2005-08-17 | 마이크로메트 에이지 | Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도 |
| DE19819846B4 (de) * | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| IL139700A (en) | 1998-06-15 | 2005-09-25 | Altarex Medical Corp | Immunotherapeutic composition for the treatment of prostate cancer |
| JP2002533134A (ja) | 1998-12-23 | 2002-10-08 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ペプチドグリカン認識タンパク質 |
| IL145941A (en) | 1999-04-28 | 2007-08-19 | Univ Texas | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| EP1194167B1 (en) | 1999-06-09 | 2009-08-19 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
| US20020002270A1 (en) | 1999-06-16 | 2002-01-03 | Raymond P. Zinkowski | Purified antigen for alzheimer's disease, and methods of obtaining and using same |
| US6964854B1 (en) | 1999-07-13 | 2005-11-15 | Science & Technology Corporation | Compositions and methods useful for the diagnosis and treatment of heparin induced thrombocytopenia/thrombosis |
| US6824780B1 (en) | 1999-10-29 | 2004-11-30 | Genentech, Inc. | Anti-tumor antibody compositions and methods of use |
| US20030031670A1 (en) | 1999-11-08 | 2003-02-13 | Jack R. Wands | Diagnosis and treatment of malignant neoplasms |
| US6835370B2 (en) | 1999-11-08 | 2004-12-28 | Rhode Island Hospital | Diagnosis and treatment of malignant neoplasms |
| US6994852B1 (en) | 1999-11-12 | 2006-02-07 | Temple University-Of The Commonwealth System Of Higher Education | Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5 |
| US6994976B1 (en) | 1999-11-19 | 2006-02-07 | Tittle Thomas V | Tr3-specific binding agents and methods for their use |
| US6319675B1 (en) | 1999-11-24 | 2001-11-20 | Millennium Pharmaceuticals, Inc. | Methods for detecting and/or identifying agents which bind and/or modulate function of “bonzo” chemokine receptor |
| US6835549B2 (en) | 2000-02-24 | 2004-12-28 | University Of Medicine & Dentistry Of New Jersey | Immunoassay method for the diagnosis of gastric intestinal metaplasia associated with gastric carcinoma |
| PT1265929E (pt) | 2000-03-23 | 2009-10-15 | Genentech Inc | Inibidores anti-c2/c2a de activação complementar |
| WO2001094413A2 (en) | 2000-06-06 | 2001-12-13 | Bristol-Myers Squibb Company | B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| WO2002010764A2 (en) | 2000-07-31 | 2002-02-07 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | SPECIFIC BINDING AGENTS FOR KSHV vIL-6 THAT NEUTRALIZE A BIOLOGICAL ACTIVITY |
| US7060802B1 (en) | 2000-09-18 | 2006-06-13 | The Trustees Of Columbia University In The City Of New York | Tumor-associated marker |
| DE60141844D1 (de) | 2000-10-02 | 2010-05-27 | Oklahoma Med Res Found | Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen |
| PA8535501A1 (es) | 2001-01-05 | 2003-07-28 | Pfizer | Anticuerpos contra el receptor del factor de crecimiento similar a insulina |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US6824778B2 (en) | 2001-04-23 | 2004-11-30 | The United States Of America As Represented By The Secretary Of The Army | Prophylactic and therapeutic monoclonal antibodies |
| AU2002303832A1 (en) | 2001-05-21 | 2002-12-03 | Beth Israel Deaconess Medical Center, Inc. | P.aeruginosa mucoid exopolysaccharide specific binding peptides |
| US7049060B2 (en) | 2001-11-05 | 2006-05-23 | Ortho-Clinical Diagnostics, Inc. | HCV anti-core monoclonal antibodies |
| RU2004127458A (ru) | 2002-02-14 | 2005-10-27 | Иммуномедикс, Инк. (Us) | Анти-cd20 антитела, их гибридные белки и способы их использования |
| JP4472351B2 (ja) | 2002-03-01 | 2010-06-02 | イミューノメディクス、インコーポレイテッド | インターナライジング抗ｃｄ７４抗体およびその使用方法 |
| CN101824090B (zh) | 2002-06-14 | 2013-01-02 | 免疫医疗公司 | 人源化单克隆抗体hPAM4 |
| CA2513113A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| MXPA05007973A (es) | 2003-01-28 | 2005-09-20 | Schering Corp | Anticuerpos especificos para celulas dendriticas plasmacitoides. |
| US7902338B2 (en) * | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| US7109304B2 (en) * | 2003-07-31 | 2006-09-19 | Immunomedics, Inc. | Humanized anti-CD19 antibodies |
| CN101218351A (zh) * | 2005-02-15 | 2008-07-09 | 杜克大学 | 抗cd19抗体及其在肿瘤学中的应用 |
| EP1899379B1 (en) * | 2005-06-20 | 2018-04-11 | E. R. Squibb & Sons, L.L.C. | Cd19 antibodies and their uses |
| JP5401314B2 (ja) * | 2006-09-08 | 2014-01-29 | メディミューン，エルエルシー | ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用 |
| WO2008081331A2 (en) * | 2006-12-29 | 2008-07-10 | Sinomab Bioscience Limited | Enhancing the level of antibody expression by framework re-engineering |
-
2008
- 2008-11-07 US US12/266,999 patent/US7902338B2/en not_active Expired - Lifetime
-
2009
- 2009-10-22 CA CA2742254A patent/CA2742254A1/en not_active Abandoned
- 2009-10-22 JP JP2011534633A patent/JP5762965B2/ja active Active
- 2009-10-22 WO PCT/US2009/061666 patent/WO2010053716A1/en not_active Ceased
- 2009-10-22 AU AU2009311461A patent/AU2009311461B2/en not_active Ceased
- 2009-10-22 EP EP09825205.9A patent/EP2352523B1/en active Active
- 2009-10-22 CN CN200980144442.0A patent/CN102209556B/zh active Active
-
2010
- 2010-10-19 US US12/907,262 patent/US8147831B2/en not_active Expired - Lifetime
-
2011
- 2011-05-05 IL IL212701A patent/IL212701A/en active IP Right Grant
-
2012
- 2012-02-16 US US13/398,214 patent/US8337840B2/en not_active Expired - Lifetime
- 2012-11-19 US US13/680,713 patent/US8486395B2/en not_active Expired - Fee Related
-
2013
- 2013-06-17 US US13/919,512 patent/US8624001B1/en not_active Expired - Fee Related
- 2013-11-22 US US14/087,799 patent/US9056917B2/en not_active Expired - Lifetime
-
2015
- 2015-05-08 US US14/707,174 patent/US20150252110A1/en not_active Abandoned
- 2015-06-10 JP JP2015117532A patent/JP5951850B2/ja active Active
-
2016
- 2016-06-08 JP JP2016114443A patent/JP2017019765A/ja active Pending
- 2016-06-27 US US15/193,583 patent/US9605071B2/en not_active Expired - Fee Related
-
2017
- 2017-02-14 US US15/432,509 patent/US20170152315A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7825605B2 (ja) | 抗ｂｔｎ３ａ抗体及びがん又は感染性障害の処置におけるその使用 | |
| JP2006500904A5 (enExample) | ||
| CA2478012A1 (en) | Internalizing anti-cd74 antibodies and methods of use | |
| CN109022465B (zh) | 多肽构建体及其用途 | |
| TWI608017B (zh) | 人化抗ｃｘｃｒ５抗體類、彼之衍生物類及彼等之用途 | |
| AU2019318031B2 (en) | Anti-CD137 antigen-binding molecule and utilization thereof | |
| JP7339948B2 (ja) | モノクローナル抗体およびその使用法 | |
| RU2004127458A (ru) | Анти-cd20 антитела, их гибридные белки и способы их использования | |
| JP2022529350A (ja) | アンタゴニスト抗ｃｄ７抗体 | |
| TW201420600A (zh) | 抗－間皮素結合蛋白質 | |
| JP2014508511A5 (enExample) | ||
| WO2015091853A2 (en) | Antibodies | |
| JP2017019765A (ja) | 改良された抗ｃｄ１９抗体 | |
| TW201300413A (zh) | 與４－１ｂｂ結合之分子類 | |
| CN112105373B (zh) | 治疗b型肝炎病毒感染的方法 | |
| WO2019137397A1 (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP7686614B2 (ja) | 癌の治療に用いるための抗ｃｄ１３７抗原結合分子 | |
| KR20170020477A (ko) | 인터페론 알파 및 오메가 항체 길항제 | |
| EP3849572A2 (en) | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist | |
| JP2019214621A (ja) | 抗ホスホリパーゼｄ４抗体を含む医薬 | |
| US20210230262A1 (en) | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist | |
| JP2025530159A (ja) | Ｃｃｒ８抗体の医学的使用および投与スケジュール | |
| US20210322547A1 (en) | Methods of treating immunotherapy-related toxicity using a gm-csf antagonist | |
| CN120077067A (zh) | B7-h3抗原结合分子 | |
| US11130805B2 (en) | Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist |